Navigation Links
RetireSafe Urges Support for Provenge Prostate Cancer Treatment
Date:11/17/2010

BALTIMORE, Nov. 17, 2010 /PRNewswire-USNewswire/ -- RetireSafe, a 400,000-supporter strong national advocacy group for older Americans, today urged the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to support the full reimbursement of costs related to the important new Provenge treatment procedure for prostate cancer patients. RetireSafe President Thair Phillips urged the Committee to "consider not only the many Americans suffering from prostate cancer, and their families, but also the millions of older Americans who are not yet directly affected by the disease, but who will, nonetheless, be affected by this decision." He said, "These seniors care very deeply about the suffering and choices of the individuals who do have prostate cancer and also about the role of government in determining the availability of the best possible medical treatment."

"The MEDCAC decision today will have a lasting effect on future research and development of innovative new medications," Phillips continued. "If the Provenge treatment is denied for reimbursement, future innovation will suffer along with millions of cancer patients," he said.  "We second Dr. Allen Lichter, head of the American Society of Clinical Oncology, that it is 'extremely chilling' to innovation in cancer research if new FDA-approved treatments against cancer must now go through a second round of efficacy and safety review from CMS, even for 'on-label' use," Phillips stated.  "That kind of rationing, after the 15-year, $1 billion development of this state-of-the-art treatment, would be beyond cruel," Phillips charged.

"The clinical effectiveness of the Provenge treatment is not in dispute," he added.   "Whether the MEDCAC admits it or not the real core of this discussion is price, and price is the very thing that should not be a point of discussion," he stated.

"Finally, we see many new Food and Drug Administration (FDA) approved drugs and treatments applauded, while others, like the Provenge treatment for prostate cancer, are attacked for supposedly being too costly," he said. "This apparent bias is troubling to seniors and serves to break the trust seniors have in the agency that has a huge impact on their everyday lives," Phillips went on to say. "This decision impacts not only prostate patients but every American, especially older Americans, and MEDCAC should carefully consider the far reaching implications of this landmark decision," he concluded.


'/>"/>
SOURCE RetireSafe
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
2. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
3. DC Patients Cooperative Urges Changes to the Proposed Medical Cannabis Marijuana Regulations
4. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
5. FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
6. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
7. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
8. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
9. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
10. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
11. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s work in cellular ... of researchers and leaders from Sanford Health were selected to participate in the ... Impact ” and receive the 2016 Pontifical Key Innovation Award at the Vatican. ...
(Date:4/28/2016)... ... 2016 , ... CastCoverz!, America’s #1 trusted brand for cast ... waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! offers ... night, weatherproof and waterproof covers for most orthopedic devices, including but not limited ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... Standards Consortium (CDISC) announces today the open availability of a new CDISC ... and catalogs for registering clinical trials. This innovative standard will make it ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and the Campaign for Tobacco-Free Kids, a leading force in the fight to ... federal, state and local policies that can help reduce tobacco use. The initiative ...
(Date:4/28/2016)... ... 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader of ... technology that marries human physiology with electromechanics. He continues that work as Director of ... of BionX , a leader in the field of prosthetic devices. , After ...
Breaking Medicine News(10 mins):